Laboratory markers of melanoma progression;A melanoma progressziójának laboratóriumi markerei

Magyar Onkologia

Volumn 47, Issue 1, 2003, Pages 89-104

  Teodóra, Bánfalvi ^a   Mariann, Édesné B ^a   Mária, Gergye ^a   Nóra, Udvarhelyi ^a   Zsolt, Orosz ^a   Katalin, Gilde ^a   Tibor, Kremmer ^a   Szabolcs, Ottó ^a   József, Tímár ^a  

^a NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION MOLECULE; CERULOPLASMIN; COPPER; CYTOKINE; LACTATE DEHYDROGENASE; MELANIN; METALLOPROTEINASE; TUMOR ANTIGEN; TUMOR MARKER; ZINC;

BIOSYNTHESIS; BLOOD; CANCER STAGING; DISEASE COURSE; HUMAN; MELANOMA; METABOLISM; REVIEW; SENSITIVITY AND SPECIFICITY; SKIN TUMOR;

ANTIGENS, NEOPLASM; CELL ADHESION MOLECULES; CERULOPLASMIN; COPPER; CYTOKINES; DISEASE PROGRESSION; HUMANS; L-LACTATE DEHYDROGENASE; MELANINS; MELANOMA; METALLOENDOPEPTIDASES; NEOPLASM STAGING; SENSITIVITY AND SPECIFICITY; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; ZINC;

EID: 0043203049     PISSN: 00250244     EISSN: 20600399     Source Type: Journal    
DOI: None     Document Type: Article

References (163)

1. Acland K, Evans V, Abraha H, et al. Serum S-100B concentrations are not useful in predicting micrometastatic disease in cutaneous malignant melanoma. Br J Dermatol 146:832-835, 2002
2. Agrup G, Falk K, Fyge K, et al. DOPA and 5-S-CD in the urine of healthy humans. Acta Dermatovener (Stockholm) 53:453-457, 1973
3. Agrup G, Falck B, Jacobsson S, et al. 5-S-cysteinyldopa in melanomas of Caucasians. Acta Dermatovener (Stockholm) 54:21-24, 1974
4. Agrup G, Agrup P, Andersson T, et al. 5 years experience of 5-S-cysteinyldopa in melanoma diagnosis. Acta Derm Venereol (Stockh) 59:381-388, 1979
5. Altomonte M, Colizzi F, Esposito G, Maio M. Circulating intercellular adhesion molecule-1 as marker of disease progression in cutaneous melanoma. N Eng J Med 327:959, 1992
6. Bánfalvi T, Malmos E. A napfény és a rosszindulatu bordaganatok. Orvosképzés 68:72-75, 1993
7. Bánfalvi T, Oberna F, Kiskoszegi A. A klinikai diagnózis megbízhatósága melanoma malignumban. Borgyógy Venerol Szle 73:3-7, 1997
8. Bánfalvi T, Gilde K, Boldizsár M, et al. Serum levels of S-100 protein and 5-S-cysteinyldopa as markers of melanoma progression. Pathol Oncol Res 5:218-223, 1999
9. Bánfalvi T, Gilde K, Bezzegh A, et al. Clinical significance of S-100 protein assay in malignant melanoma. J Tumor Marker Oncol 14:5-12, 1999
10. Bánfalvi T, Gilde K, Boldizsár M, et al. Serum concentration of 5-S-cysteinyldopa in patients with melanoma. Eur J Clin Invest 30:900-904, 2000
11. Bánfalvi T, Gilde K, Boldizsár M, et al. Use of serum S-100B protein and 5-S-cysteinyldopa to monitor the clinical course of patients with malignant melanoma. Eur J Cancer 39:164-169, 2003
12. Bánfalvi T, Udvarhelyi N, Orosz Zs, et al. Heterogenous S-100B protein expression patterns in malignant melanoma and association to the serum protein levels. Oncology (Basel) elfogadva
13. Bánfalvi T, Boldizsár M, Gergye M, et al. Comparison of prognostic significance of serum 5-S-cysteinyldopa, LDH and S-100B protein in Stage III-IV malignant melanoma. Pathol Oncol Res 8:183-186, 2002
14. Bánfalvi T, Gilde K, Édesné Boldizsár M, et al. Clinical significance of 5-S-CD monitoring in patients with malignant melanoma. Neoplasma 49:121-124, 2002
15. Bedikian AZ, Legha SS, Mavligit G. Treatment of uveal melanoma metastatic to the liver. Cancer 76:1665-1670, 1995
16. Benathan M. Modulation of 5-S-cysteinyldopa formation by tyrosinase activity and intracellular thiols in human melanoma cells. Melanoma Res 6:183-189, 1996
17. Benathan M, Labidi F. Cysteine dependent 5-S-CD formation and its regulation by glutathion in normal and epidermal melanocytes. Arch Dermatol Res 288:697-702, 1996
18. Berking C, Schlupen EM, Schrader A, et al. Tumor markers in peripheral blood of patients with malignant melanoma: multimarker RT-PCR versus a luminoimmonometric assay for S-100. Arch Dermatol Res 291:479-484, 1999
19. Blessing K, Sanders DS, Grant JJ. Comparison of immunohistochemical staining of the novel antibody melan-A with S-100 protein and HMB-45 in malignant melanoma and melanoma variants. Histopathol 32:139-146, 1998
20. Bogdahn U, Apfel R, Hahn M, et al. Autocrine tumor cell growth inhibiting activities from human malignant melanoma. Cancer Res 49:5358-5363, 1989
21. Bonfrer JMG, Korse CM, Nieweg OE, Rankin EM. The luminescens immunoassay S-100: a sensitive test to measure circulating S-100B: its prognostic value in malignant melanoma. Br J Cancer 77:2210-2214, 1998
22. Bonfrer, JMG, Korse CM. Monitoring malignant melanoma with the S-100B tumour marker. Recent Results Cancer Res 158:149-157, 2001
23. Bosserhoff A, Hein R, Bogdahn U, Buettner R. Structure and promoter analysis of the gene encoding the human melanoma inhibiting protein MIA. J Biol Chem 271:490-495, 1996
24. Bosserhoff A, Kaufmann M, Kaluza B, et al. Melanoma inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res 57:3149-3153, 1997
25. Bosserhoff A, Dreau D, Hein R, et al. Melanoma inhibitory activity (MIA) a serological marker of malignant melanoma. Recent Results Cancer Res 158:158-168, 2001
26. Bosserhoff A, Echtenacher B, Hein R, Buettner R. Functional role of melanoma inhibitory avtivity in regulation of invasion and metastasis of malignant melanoma cells in vivo. Melanoma Res 4:417-421, 2001
27. Boyano MD, Garcia-Vazquez MD, Lopez-Michelena T, et al. Soluble interleukin-2 receptor, intracellular adhesion molecule and interleukin-10 serum levels in patients with melanoma. Br J Cancer 83:847-852, 2000
28. Böni R, Burg G, Doguoglu A, et al. Immunohistochemical localization of the Ca binding S-100 proteins in normal human skin and melanocytic lesions. Br J Dermatol 137:39-43, 1997
29. Brochez L, Naeyaert JM. Serological markers for melanoma. Br J Dermatol 143:256-268, 2000
30. Brossart P, Keilholz U, Willhauck M, et al. Hematogenous spread of malignant melanoma cells in different stages of disease. J Invest Dermatol 101:887-889, 1993
31. Buer J, Probst M, Franzke A. Elevated serum levels of S-100B and survival in metastatic malignant melanoma. Br J Cancer 75:1373-1376, 1997
32. Burton CR. Malignant melanoma in the year 2000. CA Cancer J Clin 50:209-213, 2000
33. Buzaid AC, Sandler AB, Hayden CL, et al. Correlation between lipid-associated sialic acid and tumor burden in melanoma. Int J Biol Marker 4:247-250, 1994
34. Campora E, Repetto l, Giuntini P. LDH in the follow up of stage I malignant melanoma. Eur J Cancer Clin Oncol 2:277-288, 1988
35. Cho KH, Hashimoto K, Taniguchi J, et al. Immunohistochemical study of melanocytic nevus and malignant melanoma with monoclonal antibodies against S-100 subunits. Cancer 66:765-771, 1990
36. Cochran A, Wen D, Herschman H, Gaynor R. Detection of S 100 protein as an aid to the identification of melanocytic tumours. Int J Cancer 30:295-297, 1982
37. Cooper EH. Neuron-specific enolase. Int J Biol Markers 4:205-210, 1994
38. Curry BJ, Farrelly M, Hersey P. Evaluation of S-100B assay for the prediction of recurrence and prognosis in patients with AJCC stage I-III melanoma. Melanoma Res 9:557-567, 1999
39. Deichmann M, Benner A, Bock M, et al. S-100beta, MIA, LDH discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. J Clin Oncol 17:1891-1896, 1999
40. Deichmann M, Benner A, Kuner N, et al. Are responses to therapy of metastatized melanoma reflected by decreasing serum values of S-100 beta or MIA? Melanoma Res 11:291-296, 2001
41. Diepgen TL, Mahler V. The epidemiology of skin cancer. Br J Dermatol 146(Suppl 61):1-6, 2002
42. Djukanovic D, Hofmann U, Sucker A, et al. Comparison of S-100 protein and MIA protein as serum markers in malignant melanoma. Anticancer Res 20:2203-2207, 2000
43. Döme B, Somlai B, Tamásy A, et al. A cutan melanoma prognózisa és inváziós marker expressziója. Metasztázis asszociált gének. Orv Hetilap 1140:235-240, 1999
44. Dummer W, Becker JC, Schwaaf A, et al. Elevated serum levels of interleukin 10 in patients with metastatic malignant melanoma. Melanoma Res 5:67-68, 1995
45. Duray PH, Palazzo J, Gown AM, Ohuchi N. Melanoma cell heterogeneity. A study of two monoclonal antibody compared with S-100 protein in paraffin sections. Cancer 61:2460-2468, 1988
46. Einhorn LH, Burgess MA, Vallejos C. Prognostic correlations and response to treatment in advanced melanoma. Cancer Res 34:1997-2004, 1974
47. Eng W, Tschen JA. Comparison of S-100 versus hematoxylin and eosin staining in evaluating dermal invasion and peripheral margins by desmoplastic malignant melanoma. Am J Dermatopathol 22:26-29, 2000
48. Eton O, Legha S, Moon T, et al. Prognostic factors for survival of patients treated systemically for disseminated melanoma. J Clin Oncol 16:1103-1111, 1998
49. Fagnart O, Sindic Ch, Laterre Ch. Particle counting immunoassay of S-100 protein in serum. Possible relevance in tumors and ischemic disorders of the central nervous system. Clin Chem 34:1387-1391, 1988
50. Finck SJ, Giuliano AE, Morton DL. LDH and melanoma. Cancer 151:840-843, 1983
51. Franzke A, Probst-Kepper M, Buer J, et al. Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma. Br J Cancer 78:40-45, 1998
52. Gaynor R, Irie R, Morton D, Herschmann H. S-100 protein is present in cultured human malignant melanomas. Nature 286:400-401, 1980
53. Ghanem G, Lienard D, Hanson P, et al. Increased serum alpha melanocyte stimulating hormone in human malignant melanoma. Eur J Cancer Clin Oncol 22:535-536, 1986
54. Ghanem G, Loir B, Morandini R, et al. On the release and half life of serum S-100B protein in the peripheral blood of melanoma patients. Int J Cancer 94: 586-590, 2001
55. Gilde K, Terstyánszki E, Somlai B, Pulay T. Szérum lipidhez kötött sziálsav mérések melanomás gondozott betegeken. Borgyógy Venerol Szle 69:4:419-423
56. Guo HB, Stoffel-Wagner B, Bierwirth T, et al. Clinical significance of serum S-100 in metastatic malignant melanoma. Eur J Cancer 31A:1898-1902, 1995
57. Hagen EC, Vennegoor C, Schlingemann RO, et al. Correlation of histopathological characteristics with staining patterns in human melanoma assessed by monoclonal antibodies reactive on paraffin sections. Histopathology 10:689-7000, 1986
58. Hansson C, Edholm L, Agrup G, et al. The quantitative determination of 5-S-cysteinyl-dopa and dopa in normal serum and in urine from patients with malignant melanoma by means of high performance liquid chromatography. Clin Chim Acta 88:419-421, 1978
59. Hanson LO, von Schoultz E, Djureen E, et al. Prognostic value of serum S-100 protein beta in malignant melanoma. Anticancer Res 17:3071-3074, 1997
60. Hasegawa M, Takata M, Hatta N, et al. Simultaneous measurement of serum 5-S-cysteinyldopa, circulating intercellular adhesion molecule-1 and soluble interleukin-2 receptor levels in Japanese patients with malignant melanoma. Melanoma Res 7:243-251, 1997
61. Hau P, Apfel R, Wiese P, et al. Melanoma inhibiting activity (MIA/CD-RAP) is expressed in a variety of malignant tumors of mainly neuroectodermal origin. Anticancer Res 22:577-583, 2002
62. Hauschild A. The use of serological tumor markers for malignant melanoma. Onkologie 20:462-465, 1997
63. Hauschild A, Engel G, Brenner W, et al. S-100B protein detection in serum is a significant prognostic factor in metastatic melanoma. Oncology 56:338-344, 1999
64. Hauschild A, Engel G, Brenner W, et al. Predictive value of serum S-100B for monitoring patients with metastatic melanoma during chemoterapy and/or immunotherapy. Br J Dermatol 140:1065-1071, 1999
65. Hauschild A, Michaelsen J, Brenner W, et al. Prognostic significance of serum S-100 detection compared to routine blood parameters in advanced metastatic melanoma patients. Melanoma Res 9:155-161, 1999
66. Heimdal K, Hannisdal E, Gunderson S. Metastatic malignant melanoma. Eur J Cancer 25:1219-1223, 1989
67. Heizmann CW, Fritz G, Schafer BW. S-100 proteins: structure, functions and pathology. Front Biosci 1:1356-1368, 2002
68. Henze G, Dummer R, Joller-Jemelka HI, et al. Serum S-100 a marker for disease monitoring in metastatic melanoma. Dermatology 194:208-212, 1997
69. Hill BR, Levi C. Elevation of serum component in neoplastic disease. Cancer 14:513-515, 1954
70. Hirai S, Kageshita T, Kimura T, et al. Serum levels of s-ICAM, and 5-S-cysteinyldopa as markers of melanoma progression. Melanoma Res 7:58-62, 1997
71. Horikoshi T, Ito S, Wakamatsu K, et al. Evaluation of melanin-related metabolites as markers of melanoma progression. Cancer 73:629-636, 1994
72. Horikoshi T, Ito S. Serum 5-S-CD as a marker of melanoma progression. J Dermatol 19:809-813, 1992
73. Hornef S, Lux J, Ressner G. Neuronen spezifische Enolasen: ein geeigneter Tumormarker des Malignen Melanomes. Hautarzt 43:77-78, 1992
74. Hu F, Woodward Wr, Peterson L. Plasma 5-S-CD correlates with tumour size in melanoma-bearing mice. J Invest Dermatol 90:149-151, 1988
75. Hunzelmann N, Kurschat P, Hani N, et al. Applicability of reference values for the determination of serum S-100B protein as a marker of malignant melanoma in children. Br J Dermatol 146:536-539, 2002
76. Inoue S, Hasegawa K, Ito S, et al. Antimelanoma effect of 4-S-cysteaminylcatechol, an activated form of 4-Scyteaminylphenol. Cancer Res 55:2603-2607, 1995
77. Isobe T, Okuyama T. The amino acid sequence of S-100 protein and its relation to the calcium binding proteins. Eur J Biochem 89:379-388, 1978
78. Isobe T, Tsugita A, Okuyama T. The amino acid sequence and the subunit structure of bovine brain S-100 protein (PAP I-b). J Neurochem 30:921-923, 1978
79. Ito S, Kato T, Maruta K, Fujita K. Determination of DOPA, dopamine and 5-S-CD in plasma, urine and tissue samples by high performance liquid chromatography with electrochemical detection. J Chromatogr 311:154-159, 1984
80. Ito S, Wakamatsu K, Inoue S, Fujita K. Correlation between urinary melanin related metabolites and tumour weight in melanoma-bearing mice. Acta Derm Venereol 69:380-384, 1989
81. Ito S. Melanin related metabolites as markers of melanoma: a review. J Dermatol 19:802-805, 1992
82. Jury CS, McAlister EJ, MacKie RM. Rising levels of serum S100 protein precede other evidence of disease progression in patients with malignant melanoma. Br J Dermatol 143:269-274, 2000
83. Kagedal B, Petersson A. Determination of urinary 5-SCD by high performance liquid chromatography. J Chromatogr 272:287-297, 1983
84. Khansur T, Sandders J, Das SK. Evaluation of staging workup in malignant melanoma. Arch Surg 24:847-849, 1989
85. Karnell R, Kagedal B, Lindholm C, et al. The value of cysteinyldopa in the follow up of disseminated malignant melanoma. Melanoma Res 10:363-369, 2000
86. Karnell R, von Schoultz E, Hansson LO, et al. S 100B protein, 5-S-CD and 6-H-5-MI-2-carboxylic acid as biochemical markers for survival, prognosis in patients with malignant melanoma. Melanoma Res 7:393-399, 1997
87. Kaskel P, Berking C, Sander S. S-100 protein B in peripheral blood: a marker for melanoma metastases: a prospective 2-center study of 570 patients with malignant melanoma. J Am Acad Dermatol 41:962-969, 1999
88. Keilholz U, Martus P, Punt CJ, et al. Prognostic factors for survival with long term remission in patients with advanced melanoma receiving cytokine-based treatments. Eur J Cancer 38:1501-1511, 2002
89. Kelley MC, Gupta RK, Hsuec EC, et al. Tumor associated TA90 immun complex assay predicts recurrence and survival after surgical treatment of stage I-II melanoma. J Clin Oncol 19:1176-1182, 2001
90. Kernohan NM, Rankin R. S-100 protein: a prognostic indicator in cutaneous malignant melanoma? Histopathology 11:1285-1293, 1987
91. Koehler M, Bosserhoff A, von Beust G, at al. Assignment of the human melanoma inhibitory activity gene (MIA) to 19q13.32-q13.33 by fluorescence in situ hybridization (FISH). Genomics 35:265-267, 1996
92. Krahn G, Kaskel P, Sander S, et al. S100 beta is a more reliable tumor marker in peripheral blood of patients with newly occured melanoma metastases comparing to MIA, albumin and lactate-dehydrogenase. Anticancer Res 21:1311-1316, 2001
93. Liu J, Jimbow K. Development and characterization of a murine monoclonal antibody against phaeomelanin and its precursor 5-S-cysteinydopa. Melanoma Res 3:463-469, 1993
94. Lorenz J, Dippold W. Neuron specific enolase: a marker for malignant melanoma. J Natl Cancer Inst 881:1754-1755, 1989
95. Manola J, Atkins M, Ibrahim J, Kirkwood J: Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol 18:3782-3793, 2000
96. Marks R. The changing incidence and mortality of melanoma in Australia. Recent Results Cancer Res 160:113-121, 2002
97. Martenson ED, Hansson LO, Nilsson B. Serum S 100b protein as prognostic marker in malignant cuteneous melanoma. J Clin Oncol 19:824-831, 2001
98. Meral R, Duranyildiz D, Tas F, et al. Prognostic significance of melanoma inhibiting activity levels in malignant melanoma. Melanoma Res 11:627-632, 2001
99. Meyerhoffer S, Lindberg Z, Hager A, et al. Urinary excretion of 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid in children. Acta Derm Venereol 78:31-35, 1998
100. Miliotes G, Lyman GH, Cruse CW, et al. Evaluation of new putative tumour markers for melanoma. Ann Surg Oncol 3:558-563, 1996
101. Mohammed MQ, Abraha HD, Sherwood RA, et al. Serum S-100beta protein as a marker of disease activity in patients with malignant melanoma. Med Oncol 18:109-120, 2001
102. Mojamdar M, Ichihashi M, Mishima Y. Gamma glutamyl transpeptidase, tyrosinase and 5-S-CD production in melanoma cells. J Invest Dermatol 81:119-121, 1983
103. Molina R, Navarro J, Fiella X, et al. S-100 protein serum levels in patients with benign and malignant diseases: fals positive results related to liver and renal function. Tumour Biol 23:39-44, 2002
104. Moore BW, McGregor T. Chromatographic and electrophoretic fractionation of soluble proteins of brain and liver. J Biol Chem 240:1647-1653, 1965
105. Mouawad R, Benhammouda A, Rixe O, et al. Endogenous interleukin 6 levels in patients with metastatic malignant melanoma: correlation with tumour burden. Clin Cancer Res 2:1405-1409, 1996
106. Mühlbauer M, Langenbach N, Stolz W, et al. Detection of melanoma cells in the blood of melanoma patients by melanoma-inhibiting activity (MIA) reverse transcription-PCR. Clin Cancer Res 5:1099-1105, 1999
107. Nakajima T, Watanabe S, Sato Y, et al. Immunohistochemical demonstration of S-100 protein in malignant melanoma and pigmented nevus and its diagnostic application. Cancer 50:912-918, 1982
108. Nakajima T, Watanabe S, Sato Y. An immunoperoxidase study of S-100 protein distribution in normal and neoplastic tissues. Am J Surg Pathol 6:715-727, 1982
109. Nemunaitis J, Fong T, Shabe P, et al. Comparison of serum interleukin 10 (IL-10) levels between normal volunteers and patients with advanced melanoma. Cancer Invest 19:239-247, 2001
110. Nimmo JE, Grawkrodger DJ, O'Docherty CS, et al. Plasma 5-S-CD as an index of melanogenesis. Br J Dermatol 118:487-495, 1988
111. Orchard GE Comparison of immunohistochemical labelling of melanocyte differentation antibodies melan-A, tyrosinase and HMB 45 with NKIC3 and S-100 protein in evaluation of benign naevi and malignant melanoma. Histochem J 32:475-481, 2000
112. Orosz Zs. Melan-A/Mart 1 expression in various melanocytic lesions and in non-melanocytic soft tissue tumours. Histopathology 6:517-525, 1999
113. Ottó Sz, Kásler M. Rákmortalitás és-incidencia hazánkban, az európai adatok tükrében. Magyar Onkológia 46:111-117, 2002
114. Peterson L, Woodward W, Fletcher W, et al. Plasma 5-Scysteinyldopa differentiates patients with primary and metastatic melanoma from patients with dysplastic nevus syndrome and normal subjects. J Am Acad Dermatol 19:509-515, 1988
115. Prinz RA, Marangos PJ. Use of neuron specific enolase as serum marker for neuroendocrin neoplasms. Surgery 97:887-889, 1982
116. Proebstle TM, Jiang W, Hogel J, et al. Correlation of positive RT-PCR for tyrosinase in peripheral blood of malignant melanoma patients with clinical stage, survival, and other risk factors. Br J Cancer 82:118-123, 2000
117. Prota G Regulatory mechanism in melanogenesis. J Invest Dermatol 100:156S-161S, 1993
118. Quereux G, Denis M, Khammari A, et al. Prognostic value of tyrosinase reverse transciptase polymerase chain reaction in metastatic melanoma. Dermatology 203:221-225, 2001
119. Reinhold U, Ludtke-Handjery HC, Schnautz S, et al. The analysis of tyrosinase specific mRNA in blood samples of melanoma patients by RT-PCR is not a useful test for metastatic tumor progression. J Invest Dermatol 108:166-169, 1997
120. Reintgen DS, Cruse CW, Wells KE, et al. The evaluation of putative tumor markers for malignant melanoma. Ann Plast Surg 28:55-59, 1992
121. Rigel DS, Carucci JA. Malignant melanoma. Prevention, early detection and treatment in the 21 century. CA Cancer J Clin 50:215-223, 2000
122. Riley PA. Melanogenesis: realistic target for antimelanoma therapy. Eur J Cancer 27:1172-1177, 1991
123. Rorsman H, Rosengren AM, Rosengren E. A sensitive method for determination of 5-S-CD. Acta Dermatovener (Stockholm) 53: 248-251, 1973
124. Ros-Bullon MR, Sanchez-Pedreno P, Martinez-Liarte JH. Serum sialic acid in malignant melanoma patients: an ROC curve analysis. Anticancer Res 19:3619-3622, 1999
125. Ros-Bullon MR, Sanchez Pedreno P, Martinez Liarte JH. Serum zinc levels are incerased in melanoma patients. Melanoma Res 8:273-277, 1998
126. Ros-Bullon MR, Sanchez Pedreno P, Martinez Liarte JH. Serum ceruloplasmin in melanoma patients. Anticancer Res 21:629-932, 2001
127. Sasaki Y, Shimizu H, Naka W, et al. Evaluation of the clinical usefulness of measuring urinary excretion of 5-S-cysteinyldopa in melanoma: ten years experience of 50 patients. Acta Derm Venerol 77:379-381, 1998
128. Schadendorf D, Diehl S, Zuberbier T, et al. Quantitative detection of soluble adhesion molecules in sera of melanoma patients correlates with clinical stage. Dermatology 192:89-93, 1996
129. Schafer BW, Wicki R, Engelkamp D, et al. Isolation of a YAC clone covering a cluster of nine S-100 genes on a human chromosome 1q21 rationale for a new nomen-clature of the S-100 calcium-binding protein family. Genomics 25:638-643, 1995
130. Schafer BW, Heizmann CW. The S-100 family of EF hand calcium binding proteins: functions and pathology. TIBS 21:134-140, 1996
131. Scheibenbogen C, Möhler T, Haefele J, et al. Serum interleukin 8 is elevated in patients with metastatic malignant melanoma. Melanoma Res 5:179-181, 1995
132. Schlagenhauff B, Schittek B, Ellwanger U. Significance of serum protein S-100 levels in screening for metastasis: does protein S-100 enable early detection of melanoma recurrence? Melanoma Res 10:451-459, 2000
133. Schmitz C, Brenner W, Henze E, et al. Comparative study on the clinical use of protein S 100B and MIA in melanoma patients. Anticancer Res 20:5059-5063, 2000
134. Schoultz E, Hansson LO, Djureen E, et al. Prognostic value of serum analyses of S 100 B protein in malignant melanoma. Melanoma Res 6:133-137, 1996
135. Schultz ES, Diepgen TL, von den Dresch P. Clinical prognostic relevance of serum S-100b protein in malignant melanoma. Br J Dermatol 38:426-430, 1998
136. Seregeni E, Massaron S, Martinetti A. S-100 protein serum levels in cutaneous malignant melanoma. Oncol Rep 5:601-604, 1998
137. Sirott MN, Bajorin DF, Wong GYN. Prognostic factors in patients with metastatic malignant melanoma. Cancer 72:3091-3098, 1993
138. Smith B, Selby P, Southgate J, et al. Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 338:1227-1229, 1991
139. Sonneson B, Eide S, Ringborg U, et al. Tyrosinase activity in the serum of patients with malignant melanoma. Melanoma Res 5:113-116, 1995
140. Stahlecker J, Gauger A, Boss A, et al. MIA as a reliable tumor marker in the serum of patients with malignant melanoma. Anticancer Res 20:5041-5044, 2000
141. Steiner U. Melanocytes, moles and melanoma-a study on UV effects. Acta Derm Venereol Suppl (Stockholm) 168:1-31, 1991
142. Steiner U, Rosdahl I, Augustson A, Kagedal B. Urinary excretion of 5-S-CD in relation to skin type, UVB induced erythema and melanocyta proliferation in human skin. J Invest Dermatol 91:506-510, 1988
143. Suenaga Y, Katabuchi H, Okamura H, et al. Increased serum levels of 5-S-CD and intracellular adhesion molecule-1 in patients with uterine amelanotic metastasis from primary vaginal malignant melanoma. Gynecol Oncol 72:107-110, 1999
144. Takashi H, Horikoshi T, Wakamatsu K, et al. Alteration of melanoma melanogenesis by phenotypic modifiers. J Dermatol 19:814-817, 1992
145. Tegner E, Rorsman H, Rosengren E. 5-S-cysteinyldopa and pigment response to UVA light. Acta Derm Venereol 63:21-25, 1983
146. Tegner E, Agrup G, Rosengren E. The effect of UVB light on serum concentrations of 5-S-cysteinyldopa. Acta Derm Venereol 63:149-152, 1983
147. Tímár J, Rásó E, Döme B, et al. Expression and function of the AMF receptor by human melanoma in experimental and clinical systems. Clin Exp Metastasis 19:225-232, 2002
148. Tímár J, Csuka O, Orosz Zs, et al. Molecular pathology of tumor metastasis. Pathol Oncol Res 8:204-219, 2002
149. Tofani A, Cioffi P, Sciuto R, et al. S-100 and NSE as serum markers in melanoma. Acta Oncol 36:761-767, 1997
150. Tronnier M, Missler U, Grotrian K, Kock N. Does ultraviolet radiation exposure influence S-100B protein plasma levels? Br J Dermatol 138:1098-1102, 1998
151. Tsao H, Nadiminti U, Sober A, Bigby M. A meta-analysis of RT-PCR for tyrosinase mRNA as a marker for circulating tumor cells in cutaneuos melanoma. Arch Dermatol 137:325-330, 2001
152. Viac J, Misery L, Schmitt D, Claudy A. Follow up of circulating ICAM-1 in malignant melanoma. Br J Dermatol 134:604-605, 1996
153. Vuoristo MS, Laine S, Huhtala H, et al. Serum adhesion molecules and interleukin-2 receptor as marker of tumor load and prognosis in advanced cutaneous melanoma. Eur J Cancer 37:1629-1634, 2001
154. Vuoristo MS, Kellokumpu-Lehtinen P, Parvinen LM, et al. Serum matrix metalloproteinase-2 as a prognostic marker in advanced cutaneous melanoma. Acta Oncol 39:877-879, 2000
155. Vuoristo MS, Kellokompu-Lehtinen P, Laine S, et al. The value of serum S-100B and interleukins as tumor markers in advanced melanoma. Melanoma Res 10:237-241, 2000
156. Wakamatsu K, Ito S. Seasonal variations in serum concentration of 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxyl acid in healthy Japanese. Pigment Cell Res 8:132-134, 1995
157. Wakamatsu K, Ito S, Horikoshi T. Normal values of urinary excretion and serum concentration of 5-S-CD and 6-H-5MI-2-carboxyl acid, biochemical markers of melanoma progression. Melanoma Res 1:141-147, 1991
158. Westerhof W, Pavel S, Kammeyer A, et al. Melanin releated metabolites as markers of skin pigmentary system. J Invest Dermatol 89:78-81, 1987
159. Wibe E, Hannisdale E, Paus E, Aamdal S. Neuron specific enolase as prognostic factor in metastatic malignant melanoma. Eur J Cancer 28:1692-1695
160. Winzler RJ: Determinations of serum glycoproteins methods. Biochem Annal 2:279-311, 1958
161. Wimmer I, Meyer CJ, Seifert B, et al. Prognostic value of serum 5-S-cysteinyldopa for monitoring human metastatic melanoma during immunochemoterapy. Cancer Res 57:5073-5076, 1997
162. Wollina U, Hipler UC, Knoll B, et al. Serum matrix metalloproteinase-2 in patients with malignant melanoma. J Cancer Res Clin Oncol 127:631-635, 2001
163. Wollina U, Karte K, Hipler U. Serum protein S-100B in patients with malignant melanoma detected by immunoluminometric assay. J Cancer Res Clin Oncol 126:107-100, 2000